Tarveda Therapeutics

Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase 1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities.

Tarveda Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics, Health Diagnostics sector. The company focuses on Biotechnology and has secured $26.7B in funding across 180 round(s). With a team of 11-50 employees, Tarveda Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Tarveda Therapeutics, raised $2.8M. Discover more about their projects, partnerships, and impact on our platform.